Stefan H Hohnloser1, Riccardo Cappato2, Michael D Ezekowitz3, Thomas Evers4, Kurtulus Sahin5, Paulus Kirchhof6, Isabelle Ling Meng7, Martin van Eickels7, A John Camm8. 1. Department of Cardiology, Division of Clinical Electrophysiology, J.W. Goethe University, Frankfurt, Germany hohnloser@em.uni-frankfurt.de. 2. Arrhythmia and Electrophysiology Center, IRCCS Humanitas Research Hospital, Milan, Italy Humanitas Gavazzeni Hospital, Bergamo, Italy. 3. The Sidney Kimell Medical College at Thomas Jefferson University, Philadelphia, PA, USA. 4. Bayer Pharma AG, Wuppertal, Germany. 5. ClinStat GmbH, Statistics and Health Economics, Cologne, Germany. 6. Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, University of Birmingham, SWBH and UHB NHS Trusts, Birmingham, UK Department of Cardiovascular Medicine, Hospital of the University of Münster, Münster, Germany. 7. Global Medical Affairs, Bayer HealthCare, Berlin, Germany. 8. Division of Clinical Sciences, St George's, University of London, London, UK.
Abstract
AIMS: We compared patient-reported treatment satisfaction and the economic impact of anticoagulation therapy with rivaroxaban vs. vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation undergoing elective cardioversion procedures. METHODS AND RESULTS: The current study is a post hoc analysis of the prospective, multicentre X-VeRT (EXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in subjects with non-valvular aTrial fibrillation scheduled for cardioversion) trial. Patient-reported treatment satisfaction with anticoagulation therapy was assessed using the Treatment Satisfaction Questionnaire for Medication version II in seven countries (US, UK, Canada, Germany, France, Italy, and the Netherlands). An economic model was also developed to estimate the impact of postponed cardioversions for two countries (UK and Italy). This model estimated the total costs of cardioversion, taking into consideration the costs for drug therapy (including extended treatment duration due to cardioversion postponement), international normalized ratio monitoring of VKAs, the cardioversion procedure, and rescheduling the procedure. These costs were linked to the respective X-VeRT study data to estimate the total costs. Patients receiving rivaroxaban in the delayed cardioversion group had significantly higher scores for Convenience, Effectiveness, and Global satisfaction (81.74 vs. 65.78; 39.41 vs. 32.95; and 82.07 vs. 66.74, respectively; P < 0.0001). Based on the total patient population included in the treatment satisfaction substudy (n = 632) in the delayed cardioversion group in X-VeRT, the use of rivaroxaban was estimated to result in a saving of £421 and €360 per patient in UK and Italian settings, respectively. CONCLUSION: The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared with that of VKA.
AIMS: We compared patient-reported treatment satisfaction and the economic impact of anticoagulation therapy with rivaroxaban vs. vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation undergoing elective cardioversion procedures. METHODS AND RESULTS: The current study is a post hoc analysis of the prospective, multicentre X-VeRT (EXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in subjects with non-valvular aTrial fibrillation scheduled for cardioversion) trial. Patient-reported treatment satisfaction with anticoagulation therapy was assessed using the Treatment Satisfaction Questionnaire for Medication version II in seven countries (US, UK, Canada, Germany, France, Italy, and the Netherlands). An economic model was also developed to estimate the impact of postponed cardioversions for two countries (UK and Italy). This model estimated the total costs of cardioversion, taking into consideration the costs for drug therapy (including extended treatment duration due to cardioversion postponement), international normalized ratio monitoring of VKAs, the cardioversion procedure, and rescheduling the procedure. These costs were linked to the respective X-VeRT study data to estimate the total costs. Patients receiving rivaroxaban in the delayed cardioversion group had significantly higher scores for Convenience, Effectiveness, and Global satisfaction (81.74 vs. 65.78; 39.41 vs. 32.95; and 82.07 vs. 66.74, respectively; P < 0.0001). Based on the total patient population included in the treatment satisfaction substudy (n = 632) in the delayed cardioversion group in X-VeRT, the use of rivaroxaban was estimated to result in a saving of £421 and €360 per patient in UK and Italian settings, respectively. CONCLUSION: The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared with that of VKA.
Authors: Michael D Ezekowitz; Riccardo Cappato; Allan L Klein; A John Camm; Chang-Sheng Ma; Jean-Yves Le Heuzey; Mario Talajic; Maurício I Scanavacca; Panos E Vardas; Paulus Kirchhof; Stefan H Hohnloser; Melanie Hemmrich; Vivian Lanius; Isabelle Ling Meng; Peter Wildgoose; Martin van Eickels Journal: Am Heart J Date: 2014-01-14 Impact factor: 4.749
Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof Journal: Europace Date: 2012-08-24 Impact factor: 5.214
Authors: Riccardo Cappato; Michael D Ezekowitz; Allan L Klein; A John Camm; Chang-Sheng Ma; Jean-Yves Le Heuzey; Mario Talajic; Maurício Scanavacca; Panos E Vardas; Paulus Kirchhof; Melanie Hemmrich; Vivian Lanius; Isabelle Ling Meng; Peter Wildgoose; Martin van Eickels; Stefan H Hohnloser Journal: Eur Heart J Date: 2014-09-02 Impact factor: 29.983
Authors: Christoph Stellbrink; Uwe Nixdorff; Thomas Hofmann; Walter Lehmacher; Werner Günther Daniel; Peter Hanrath; Christoph Geller; Andreas Mügge; Walter Sehnert; Caroline Schmidt-Lucke; Jan-André Schmidt-Lucke Journal: Circulation Date: 2004-02-16 Impact factor: 29.690
Authors: Luke Bamber; Maria Y Wang; Martin H Prins; Cathleen Ciniglio; Rupert Bauersachs; Anthonie W A Lensing; Stefan J Cano Journal: Thromb Haemost Date: 2013-07-11 Impact factor: 5.249
Authors: J H H Deuling; R P Vermeulen; M D Smit; J M A A van der Maaten; H M Boersema; A F M van den Heuvel; I C Van Gelder Journal: Neth Heart J Date: 2012-04 Impact factor: 2.380
Authors: Z Sharif; B Srinivas; I Tiedt; N Ryan; M Awadalla; V Sullivan; D P Foley; T Gumbrielle; B McAdam; R G Sheahan Journal: Ir J Med Sci Date: 2017-02-24 Impact factor: 1.568
Authors: Andreas Goette; Winghan J Kwong; Michael D Ezekowitz; Maciej Banach; Soren P Hjortshoj; Dmitry Zamoryakhin; Gregory Y H Lip Journal: Europace Date: 2018-12-01 Impact factor: 5.214
Authors: Craig I Coleman; Sylvia Haas; Alexander G G Turpie; Silvia Kuhls; Susanne Hess; Thomas Evers; Pierre Amarenco; Paulus Kirchhof; A John Camm Journal: Clin Cardiol Date: 2016-06-30 Impact factor: 2.882